Cargando…
Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma
BACKGROUND: Cavernous angiomas (CAs) affect 0.5% of the population, predisposing to serious neurologic sequelae from brain bleeding. A leaky gut epithelium associated with a permissive gut microbiome, was identified in patients who develop CAs, favoring lipid polysaccharide producing bacterial speci...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984539/ https://www.ncbi.nlm.nih.gov/pubmed/36869161 http://dx.doi.org/10.1038/s43856-023-00265-1 |
_version_ | 1784900766226448384 |
---|---|
author | Srinath, Abhinav Xie, Bingqing Li, Ying Sone, Je Yeong Romanos, Sharbel Chen, Chang Sharma, Anukriti Polster, Sean Dorrestein, Pieter C. Weldon, Kelly C. DeBiasse, Dorothy Moore, Thomas Lightle, Rhonda Koskimäki, Janne Zhang, Dongdong Stadnik, Agnieszka Piedad, Kristina Hagan, Matthew Shkoukani, Abdallah Carrión-Penagos, Julián Bi, Dehua Shen, Le Shenkar, Robert Ji, Yuan Sidebottom, Ashley Pamer, Eric Gilbert, Jack A. Kahn, Mark L. D’Souza, Mark Sulakhe, Dinanath Awad, Issam A. Girard, Romuald |
author_facet | Srinath, Abhinav Xie, Bingqing Li, Ying Sone, Je Yeong Romanos, Sharbel Chen, Chang Sharma, Anukriti Polster, Sean Dorrestein, Pieter C. Weldon, Kelly C. DeBiasse, Dorothy Moore, Thomas Lightle, Rhonda Koskimäki, Janne Zhang, Dongdong Stadnik, Agnieszka Piedad, Kristina Hagan, Matthew Shkoukani, Abdallah Carrión-Penagos, Julián Bi, Dehua Shen, Le Shenkar, Robert Ji, Yuan Sidebottom, Ashley Pamer, Eric Gilbert, Jack A. Kahn, Mark L. D’Souza, Mark Sulakhe, Dinanath Awad, Issam A. Girard, Romuald |
author_sort | Srinath, Abhinav |
collection | PubMed |
description | BACKGROUND: Cavernous angiomas (CAs) affect 0.5% of the population, predisposing to serious neurologic sequelae from brain bleeding. A leaky gut epithelium associated with a permissive gut microbiome, was identified in patients who develop CAs, favoring lipid polysaccharide producing bacterial species. Micro-ribonucleic acids along with plasma levels of proteins reflecting angiogenesis and inflammation were also previously correlated with CA and CA with symptomatic hemorrhage. METHODS: The plasma metabolome of CA patients and CA patients with symptomatic hemorrhage was assessed using liquid-chromatography mass spectrometry. Differential metabolites were identified using partial least squares-discriminant analysis (p < 0.05, FDR corrected). Interactions between these metabolites and the previously established CA transcriptome, microbiome, and differential proteins were queried for mechanistic relevance. Differential metabolites in CA patients with symptomatic hemorrhage were then validated in an independent, propensity matched cohort. A machine learning-implemented, Bayesian approach was used to integrate proteins, micro-RNAs and metabolites to develop a diagnostic model for CA patients with symptomatic hemorrhage. RESULTS: Here we identify plasma metabolites, including cholic acid and hypoxanthine distinguishing CA patients, while arachidonic and linoleic acids distinguish those with symptomatic hemorrhage. Plasma metabolites are linked to the permissive microbiome genes, and to previously implicated disease mechanisms. The metabolites distinguishing CA with symptomatic hemorrhage are validated in an independent propensity-matched cohort, and their integration, along with levels of circulating miRNAs, enhance the performance of plasma protein biomarkers (up to 85% sensitivity and 80% specificity). CONCLUSIONS: Plasma metabolites reflect CAs and their hemorrhagic activity. A model of their multiomic integration is applicable to other pathologies. |
format | Online Article Text |
id | pubmed-9984539 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-99845392023-03-05 Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma Srinath, Abhinav Xie, Bingqing Li, Ying Sone, Je Yeong Romanos, Sharbel Chen, Chang Sharma, Anukriti Polster, Sean Dorrestein, Pieter C. Weldon, Kelly C. DeBiasse, Dorothy Moore, Thomas Lightle, Rhonda Koskimäki, Janne Zhang, Dongdong Stadnik, Agnieszka Piedad, Kristina Hagan, Matthew Shkoukani, Abdallah Carrión-Penagos, Julián Bi, Dehua Shen, Le Shenkar, Robert Ji, Yuan Sidebottom, Ashley Pamer, Eric Gilbert, Jack A. Kahn, Mark L. D’Souza, Mark Sulakhe, Dinanath Awad, Issam A. Girard, Romuald Commun Med (Lond) Article BACKGROUND: Cavernous angiomas (CAs) affect 0.5% of the population, predisposing to serious neurologic sequelae from brain bleeding. A leaky gut epithelium associated with a permissive gut microbiome, was identified in patients who develop CAs, favoring lipid polysaccharide producing bacterial species. Micro-ribonucleic acids along with plasma levels of proteins reflecting angiogenesis and inflammation were also previously correlated with CA and CA with symptomatic hemorrhage. METHODS: The plasma metabolome of CA patients and CA patients with symptomatic hemorrhage was assessed using liquid-chromatography mass spectrometry. Differential metabolites were identified using partial least squares-discriminant analysis (p < 0.05, FDR corrected). Interactions between these metabolites and the previously established CA transcriptome, microbiome, and differential proteins were queried for mechanistic relevance. Differential metabolites in CA patients with symptomatic hemorrhage were then validated in an independent, propensity matched cohort. A machine learning-implemented, Bayesian approach was used to integrate proteins, micro-RNAs and metabolites to develop a diagnostic model for CA patients with symptomatic hemorrhage. RESULTS: Here we identify plasma metabolites, including cholic acid and hypoxanthine distinguishing CA patients, while arachidonic and linoleic acids distinguish those with symptomatic hemorrhage. Plasma metabolites are linked to the permissive microbiome genes, and to previously implicated disease mechanisms. The metabolites distinguishing CA with symptomatic hemorrhage are validated in an independent propensity-matched cohort, and their integration, along with levels of circulating miRNAs, enhance the performance of plasma protein biomarkers (up to 85% sensitivity and 80% specificity). CONCLUSIONS: Plasma metabolites reflect CAs and their hemorrhagic activity. A model of their multiomic integration is applicable to other pathologies. Nature Publishing Group UK 2023-03-03 /pmc/articles/PMC9984539/ /pubmed/36869161 http://dx.doi.org/10.1038/s43856-023-00265-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Srinath, Abhinav Xie, Bingqing Li, Ying Sone, Je Yeong Romanos, Sharbel Chen, Chang Sharma, Anukriti Polster, Sean Dorrestein, Pieter C. Weldon, Kelly C. DeBiasse, Dorothy Moore, Thomas Lightle, Rhonda Koskimäki, Janne Zhang, Dongdong Stadnik, Agnieszka Piedad, Kristina Hagan, Matthew Shkoukani, Abdallah Carrión-Penagos, Julián Bi, Dehua Shen, Le Shenkar, Robert Ji, Yuan Sidebottom, Ashley Pamer, Eric Gilbert, Jack A. Kahn, Mark L. D’Souza, Mark Sulakhe, Dinanath Awad, Issam A. Girard, Romuald Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma |
title | Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma |
title_full | Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma |
title_fullStr | Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma |
title_full_unstemmed | Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma |
title_short | Plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma |
title_sort | plasma metabolites with mechanistic and clinical links to the neurovascular disease cavernous angioma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984539/ https://www.ncbi.nlm.nih.gov/pubmed/36869161 http://dx.doi.org/10.1038/s43856-023-00265-1 |
work_keys_str_mv | AT srinathabhinav plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT xiebingqing plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT liying plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT sonejeyeong plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT romanossharbel plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT chenchang plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT sharmaanukriti plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT polstersean plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT dorresteinpieterc plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT weldonkellyc plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT debiassedorothy plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT moorethomas plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT lightlerhonda plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT koskimakijanne plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT zhangdongdong plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT stadnikagnieszka plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT piedadkristina plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT haganmatthew plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT shkoukaniabdallah plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT carrionpenagosjulian plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT bidehua plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT shenle plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT shenkarrobert plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT jiyuan plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT sidebottomashley plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT pamereric plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT gilbertjacka plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT kahnmarkl plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT dsouzamark plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT sulakhedinanath plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT awadissama plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma AT girardromuald plasmametaboliteswithmechanisticandclinicallinkstotheneurovasculardiseasecavernousangioma |